| Trial name or title |
Study of EZ‐2053 in the prophylaxis of acute pulmonary allograft rejection |
| Methods |
A double‐blind, placebo‐controlled, multicenter, dose‐ranging study of an anti‐human‐T‐lymphocyte immune globulin (EZ‐2053) in the prophylaxis of acute pulmonary allograft rejection |
| Participants |
Adult recipients of primary pulmonary allograft(s) |
| Interventions |
Patients randomised to receive one infusion of EZ‐2053 9 mg/kg or placebo through a central venous catheter, each day for 5 days following transplant surgery |
| Outcomes |
Primary outcome: first occurrence of death, graft loss, acute rejection and/or loss to follow‐up between groups who receive 9 mg/kg or placebo within 12 months |
| Starting date |
March 2005 |
| Contact information |
Manager of Regulatory Affairs, Fresenius Biotech North America |
| Notes |
Study completed January 2011. No published results available |
